New White Paper: The Intersection of Rare Diseases and Advanced Therapies and What it Means for Clinical Development
Read the press release for the latest whitepaper on advanced therapies and rare diseases published by Xtalks and Medpace.
Spotlight on Rare Disease Clinical Development
There is a lot of uncertainty in the world right now, but one thing for certain is that rare disease and orphan indication clinical research…
Webinar: How A Deeper Understanding of Chronic Kidney Disease Is Impacting Clinical Development
Medpace’s experts will be discussing important topics from both a medical and operational perspective.
The Evolving Landscape of Therapeutic and Diagnostic Radiopharmaceuticals
In a new article, experts from Medpace’s radiation oncology, imaging, regulatory, and operational teams discuss the growing space of radiopharmaceutical development.
Rare Disease Spotlight: Acromegaly
Learn more about acromegaly and our capabilities for clinical trials.
Operationalizing Complex Innovative Trial Design (FDA’s New Approach)
One of the FDA’s recent initiatives centers on operationalizing complex innovative trial design. Learn more about the types of trials the FDA consider innovative and the…
Cell and Gene Therapies: Making the Leap from Lab to Clinic
In a new whitepaper, cell and gene therapy experts in medical, operational, and regulatory come together to give insights from past trials. Read now.
The Key to Winning at Your Drug Development Strategy
Medpace was recently featured in a whitepaper "Winning at Your Drug Development Strategy: a Playbook for Emerging Biotechs” written by Labiotech - a leading digital…
COVID-19 Webinars – Medpace Assembles Team of Experts to Discuss Considerations for Future SARS-CoV-2 Development
In these upcoming webinars, experts from Medpace’s medical department, regulatory, and operational teams will provide insights and considerations on how to accelerate product development for…
Rare Disease Webinar Series: Watch Now
Medpace gathered experts in all areas of rare disease clinical research and created a three part webinar series. All three parts are now on-demand and…